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Objective: The in vitro activity of apalcillin plus Ro 48-1220, a novel penam sulfone 13-lactamase inhibitor, was 
compared with apalcillin alone, piperacillinhazobactam. ticarcillin/clavulanic acid, amoxicillin/clavulanic acid, imipenem, 
ceftazidime and cefepime. 
Methods: Agar dilution and broth microdilution testing of 854 bacterial strains, subcultured from frozen stocks 
incubated for 24 h in 5% carbon dioxide, was carried out to determine the minimum bactericidal (MBC) and minimum 
inhibitory concentrations (MIC) of each of the study drugs in accordance with the NCCLS M26-T method. 
Results: Apalcillin/Ro 48-1220 was active against all gram-negative aerobic and anaerobic isolates except Klebsiella 
oxytoca (MI& 32 pg/rnL). Among the Enterobacteriaceae, synergy for apalcillin/Ro 48-1220 (4pg/mLfixed concentration) 
vs apalcillin alone was demonstrated for nearly all species when comparing MlCw results. Apalcillin/Ro 48-1220 was 
highly potent against 13-lactamase-producing Moraxella catarrhalis, Haemophilus influenzae and Neisseria gonorrhoeae 
(MICs 1 1  pg/mL). However, much of this activity was due to the direct antimicrobial action of Ro 48-1220 alone (MICs 
5 4  pg/mL). All Pseudomonas aeruginosa, Stenotrophomonas (Xanthomonas) maltophilia and Acinetobacter species 
were inhibited by apalcillinRo 48-1220 (MICso 0.25 to 4 Fg/mL). For the aerobic gram-positive organisms, none of the 
drugs tested were consistently effective against oxacillin-resistant staphylococci, Corynebacteriurn jeikeium and 
Enterococcus species other than E. faecalis. Apalcillin/Ro 48-1220 was as effective as piperacillinhazobactam against 
fscherichia coli producing extended-spectrum TEM enzymes, but less active against isolates producing SHV-type iJ- 
lactamases. When tested against 204 ceftazidime-, gentamicin- or fluoroquinolone-resistant organisms, 78%. 91% and 
66% of strains, respectively, were susceptible to apalcillin/Ro 48-1220 (516 pg/mL). 
Conclusions: Apalcillin/Ro 48-1220 is bactericidal with a modest inoculum effect; its wide spectrum of activity favors 
continued studies of spectrum, pharmacokinetics and in vivo efficacy. 
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The production of B-lactamases, enzymes capable of 
hydrolyzing the B-lactam ring, has become the 
principal mechanism responsible for microbial resis- 
tance to the R-lactam drugs [l-31. These B-lactamases 
have been present in the environment for decades 
and can be either chromosome- or plasmid-mediated. 
Attempts to overcome this resistance problem by 
designing B-lactams that are more stable or resistant to 
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enzyme hydrolyses have been only moderately success- 
ful because of the subsequent emergence of extended- 
spectrum B-lactamases [2,4-81. These enzymes deter- 
mine resistance to the newer cephalosporins and 
monobactams [2,4]. An alternative approach has been 
the use of B-lactamase-inhibitor co-drugs, a concept 
which gained popularity with the discovery and clinical 
applications of clavulanic acid and penicillanic acid 
sulfones [9-171. 
In an early study reported by Neu and Fu [16], 
clavulanic acid alone demonstrated activity against 
some fastidious bacteria (Neisseria gonorrhoeae, Haemo- 
philus injuenzae) and synergy when combined with 
penicillins (amoxicillin or ticarcillin) or cephalosporins 
against 8-lactamase-producing Staphylococcus aureus 
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and many Enterobacteriaceae. Two other inhibitors, 
sulbactam and tazobactam, have also been developed 
for clinical use [ll-15,17-191. Sulbactam alone is 
active against N. gonorrhoeae and, combined with 
ampican, provides synergistic activity against several 
penicfinase-producing organisms such as Staphylococnrs 
species, H. infuenzae, N. gonorrhoeae and various enteric 
bacilli [13]. Tazobactam when combined with pipera- 
cillin has demonstrated a wide spectrum of activity 
particularly against some gram-positive cocci and 
anaerobic bacteria [18]. When challenged by contem- 
porary, clinically important B-lactamases (TEM or 
SHV-derived), clavulanic acid and tazobactam were 
equally active and generally more potent as inhibitors 
than sulbactam [20]. 
The activity of apalcillin (formerly PC-904) or 
sodium 6- [D(-)-alpha-(hydroxy-1,5-naphthyridine-3- 
carboxamido)phenylacetamido]-penicillanate has been 
previously observed to exhibit broad-spectrum anti- 
microbial activity, especially against Pseudornonas 
aeruginosa [14,21-241. Apalcillin was also combined 
with R o  48-1220 [25], a novel penam sulfone B- 
lactamase inhibitor (Figure 1) developed by H o h a n n -  
La Roche Research (Basel, Switzerland). All in vitro 
experiments were conducted according to the 
standardized procedures recommended by the National 
Committee for Clinical Laboratory Standards (NCCLS) 
[26,27]. 
MATERIALS AND METHODS 
Antimicrobial agents 
The antimicrobial agents tested in the study were 
obtained from the following sources: Apalcillin and 
apalcillin/Ro 48-1220 (at a fixed concentration of 2 or 
4 pg/mL) from Hohann-La Roche; piperadin and 
tazobactam (4 pg/mL) from Lederle Laboratories (Pearl 
River, N Y ) ;  amoxicillin, ticarcillin and clavulanic acid 
(2 pg/mL when tested with ticarcillin and a 2:l ratio 
when tested with amoxicillin) from Smith-Kline 
Beecham (Philadelphia, PA); cehzidime fi-om Eli Lilly 
and Co. (Indianapolis, IN); cefepime from Bristol- 
Myers Squibb (Wallingford, CT); and imipenem from 
Merck Sharpe & Dohme (West Point, PA). 
Bacterial isolates 
The 854 organisms tested were recent clinical isolates, 
usually cultured from sterile body sites and the blood- 
stream in patients at the University of Iowa Hospitals 
and Clinics (Iowa City, IA). The bacterial strains 
consisted of Enterobacteriaceae (250 strains from 17 
species), H .  infuenzae (50 strains, 40% 8-lactamase 
producers and 20% ampicillin-resistant but enzyme- 
negative), Moraxella catarrhalis (30 strains, 67% R- 
lactamase producers), N. gonorrhoeae (49 strains, 39% 
penicillinase-producing, for example, PPNG), other 
Neisseria species (20 strains), Acinetobacter species (20 
strains), Pseudornonas species (53 strains from three 
species), Xanthomonas maltophilia (20 strains), Bacteroides 
fragilis (31 strains), Staphylococcus species (84 strains, 
12% oxacillin-resistant), Streptococcus species (1 10 
strains), enterococci (42 strains from nine species), 
Corynebacteriurn jeikeium (1 1 strains), gram-positive 
anaerobes (34 strains) and some miscellaneous gram- 
positive and -negative organisms (14 strains from five 
species). In addition, 35 bacterial strains (12 Escherichia 
coli, 21 Klebsiella pneumoniae, and two Klebsiella 
oxytoca) that produced extended-spectrum B-lacta- 
mases (ESBLs) were processed (see Table 5). ESBL 
status was defined by resistance to third-generation 
cephalosporins and increased susceptibility to the 
cephem in the presence of clavulanic acid at 2 pg/mL. 
Bactericidal action of apalcillin/Ro 48-1220 was 
determined against three NCCLS quality-control 
strains [26,27] and seven selected clinical isolates of 
Enterobacteriaceae. 
Susceptibility testing methods 
All agar dilution and broth microdilution testing was 
performed according to the methods recommended by 
the NCCLS [26,27]. Organisms were subcultured 
twice from frozen stocks and then incubated for 24 h 
in 5% C02 before being tested. Broth micro- 
dilution trays were manufactured by Prepared Media 
Laboratories (Tualatin, OR) and frozen at -70 "C until 
used. Minimum inhibitory concentrations (MICs) 
were defined as the lowest concentration of drug that 
prevented organism growth. Minimum bactericidal 
concentrations (MBCs) were determined according to 
the NCCLS M26-T method. Streptococcus pneumoniae, 
fastidious Streptococcus species and C. jeikeium were 
tested on Mueller-Hinton agar supplemented with 5% 
sheep blood, H. intuenrae was tested in Haemophilus 
test medium (HTM broth) and Neisseria species on 
supplemented GC agar base as recommended by the 
NCCLS procedures [26]. Willcins-Chalgren agar 
(Difco Laboratories, Detroit, MI) was used for testing 
the anaerobic organisms as described in the Mll-A3 
document [27]. 
Testing or medium conditions were altered for 
the agar dilution procedure to identify the effect of 
inoculum concentration, pH, C02 incubation, sheep 
blood supplement and magnesium content on the 
apalcillin/Ro 48-1220 MIC. The agar MIC and 
both MIC results for apalcillin and apalcillin/Ro 48- 
1220 were also compared to analyze the method effect 
dilution test endpoints. Interpretive criteria used for 
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apalcillin and apalc&n/Ro 48-1220 MICs were as 
those for similar antipseudomod penicillins combined 
with an enzyme inhibitor, such as piperaclllid 
tazobactam and ticarcillin/clavulanic acid [26,27]. Afier 
reviewing the pharmacokinetic data available for 
apalcillin [28], these tentative criteria appear tenable for 
comparison purposes. 
Table 1 summarizes the MIC results for the 510 
gram-negative bacterial strains tested. Cefepime and 
imipenem were the most potent drugs against the 
Enterobacteriaceae with MIC9o ranges of 50.5 
to 2 pg/mL and 50.25 to 4 pg/mL, respectively. 
Cehzidime was less active against Citrobacter freundii, 
Enterobacter aerogenes and Enterobacter cloacae species with 
resistant MICws >16 pg/mL. Synergy (ifMIC lowered 
by four-fold or greater) for the apalcillin/Ro 48-1220 
combination (2 or 4 pg/mL fixed concentration) vs 
apalc&n alone was demonstrated against all enteric 
species except Enterobacter agglomerans, K .  oxytoca and 
Providencia stuartii. Among the Klebsiella species, five 
strains were resistant to apalcillin (MICs 2128 pg/mL). 
One K .  oxytoca strain was inhibited by apalcillin/Ro 
48-1220 at 1/4 pg/mL. All other strains were not 
inhibited by 2 pg/mL of Ro 48-1220, but three 
organisms had MICs of 32 or 64 pg/mL when 
combined with 4 pg/mL of R o  48-1220. The strain 
completely unresponsive to R o  48-1220 inhibition 
was a K .  oxytoca isolate. The apalcillin/Ro 48-1220 (4 
pg/mL) MICw range was 0.5 to 32 pg/mL, and these 
results represented a two- to >128-fold reduction in 
MICw compared with the apalcillin MIC alone. The 
average MIC decrease produced by the R o  48-1220 
inhibition was eight-fold. 
Many organisms characteristically producing chro- 
mosomally mediated cephalosporinases (C. freundii, E. 
aerogenes, E .  cloacae) appear to respond synergistically to 
the apalcillin/Ro 48-1220 combination. In addition, 
among the species producing chromosome-mediated 
cephalosporinases, there were 19 strains (eight C. 
freundii, 11 Enterobacter species) that were resistant to 
ceftazidime, but susceptible to cefepime. Apalcillin/Ro 
48-1220 (4 pg/mL) inhibited all of these cited strains 
at 5 16/4 pg/mL. Among the B-lactamase-inhibitor 
combination drugs, the rank order of activity and 
spectrum was: apalcillin/Ro 48-1220 (average MIC90, 
2 pg/mL) > piperacillin/tazobactam > ticarcillin/ 
clavulanic acid > amoxicillin/clavulanic acid. 
Among the non-enteric gram-negative organisms, 
M. catarrhalis (including R-lactamase producers) was the 
most susceptible to apalcilhn/Ro 48-1220 and no drug 
tested had a MIC90 greater than 1 pg/mL. Synergy 
was apparent for apalcillin/Ro 48-1220 against B- 
lactamase-producing H.  influenrae and N. gonorrhoeae 
(MICs 5 1 pg/mL). Although no reduction in apalcillin 
MICs was demonstrated against R-lactamase-negative, 
ampicillin-resistant or -susceptible H.  infuenzae, all 
strains were susceptible (al l  MICs 51 pg/mL) to both 
apalcillin and apalc&n/Ro 48-1220. However, the R o  
48-1220 activity alone inhibited many Neisseria species 
and M. catarrhalis strains, using the fixed 4 pg/mL level 
in the in vitro tests. Thus, the apalcillin/Ro 48-1220 
MIC90 was observed at the lowest tested dilution 
for penicillin-susceptible as well as the penicdinase- 
producing strains. These lower apalcillin/Ro 48- 
1220 MICs compared with apalcillin alone were not 
secondary to any enzyme inhibitory qualities of R o  48- 
1220, but were the result of its direct antimicrobial 
activity (data not shown). 
Apalcillin/Ro 48-1220 was the most potent of the 
B-lactam/B-lactamase-inhibitor combinations tested 
against l? aeruginosa, S. maltophilia and Acinetobacter 
species (MIC90 0.25 to 4 pg/mL). l? aeruginosa 
strains were susceptible (MICs 532 p g / d )  to 
apalcillin/Ro 48-1220 only. Apalcillin/Ro 48-1220 
was slightly more potent (MICw 2 pg/mL) compared 
with ticarcillin/clavulanic acid (MIC90 4 pg/mL) 
against the S. maltophilia strains tested. R o  48-1220 
alone inhibited 80% of Acinetobacter species isolates at 
Synergy w a s  also demonstrated against B. fiaglis 
when apalcilhn was combined with R o  48-1220. 
The MIc90 was decreased from > 128 to 8 pg/mL. 
All strains of anaerobic gram-negative bacilli were 
considered susceptible (MICs 5 32/4 pg/mL) to 
apalcillin/Ro 48-1 220 using interpretive criteria for 
ticarcillin/clavulanic acid. 
Table 2 lists the results for the 288 gram-positive 
isolates tested. All of the drugs tested were active against 
oxacillin-susceptible staphylococci, with an overall 
MIC9o range of 5 0.25 to 16 pg/mL. In fact, the only 
potential non-susceptible MIC90 value observed was 
for ceftazidime (MIC90 16 pg/mL) when tested against 
the coagulase-negative staphylococci. The staphylo- 
coccal penicillinases were inhibited by R o  48-1220, 
which decreased the apalcillin MICw four- to 16-fold, 
depending on the tested oxacillin-susceptible species 
(Table 2). Apalcillin/Ro 48-1220 had the lowest 
MIC9o (16 pg/mL) against oxacan-resistant S. 
aureus, although these organisms should remain classi- 
fied as resistant to B-lactam/B-lactamase-inhlbitor 
combinations [26]. 
4 pg/mL. 
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Table 1 In vitro activity of antimicrobial drugs tested against 510 recent gram-negative clinical isolates 
MIC (pg/mL) 
Organism (n) Antimicrobial agent 50% 90% Range 
Citrobacter diversus (1 0) 
Citrobacterfreundii (20) 
Enferobacter aerogenes (20) 
Enferobacter agglomeram (10) 
Enterobacter cloacae (20) 
Escherichia coli (20) 
Apalcillin/Ro 48-1220 (2 pg/mL) 
Apalc&n/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Cehzidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 pg/mL) 
Apalc&n/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
ArnoxicilldClavulanate 
Imipenem 
Cefiazidime 
Cefepime 
Apalc&n/Ro 48-1220 (2 pg/mL) 
ApalcillidRo 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
AmoxicdIdClavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 pg/mL) 
ApalcillidRo 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
TicarcdldClavulanate 
AmoxicillidClavulanate 
Imipenem 
Cefcazidime 
Cefepime 
Apalc&n/Ro 48-1220 (2 pg/rnL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarc&n/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Cehzidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 pg/mL) 
ApalcillidRo 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
TicarcdldClavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Cefrazidime 
Cefepime 
1 
1 
8 
2 
4 
2 
10.25 
50.5 
50.5 
2 
1 
16 
2 
64 
>8 
50.25 
50.5 
10.5 
2 
2 
8 
4 
4 
>8 
0.5 
50.5 
50.5 
0.5 
0.5 
0.5 
1 
2 
2 '  
10.25 
50.5 
50.5 
2 
2 
2 
2 
8 
>8 
10.25 
50.5 
50.5 
1 
0.5 
1 
1 
4 
2 
50.25 
50.5 
50.5 
2 
2 
8 
4 
4 
4 
10.25 
50.5 
50.5 
2 
2 
>128 
16 
> 128 
>8 
1 
>16 
1 
16 
8 
128 
64 
128 
>8 
1 
216 
10.5 
2 
2 
4 
2 
4 
4 
10.25 
50.5 
50.5 
8 
4 
> 128 
32 
128 
>8 
0.5 
>16 
1 
2 
2 
>128 
4 
32 
8 
50.25 
50.5 
50.5 
1-2 
1-2 
4-16 
1-4 
2-4 
2-4 
50.25 
50.5 
10.5 
1-128 
0.5-8 
1->128 
1->128 
1->128 
>8 
50.25-1 
10.5->16 
50.5-4 
0.5-128 
1-128 
1->128 
1-128 
1->128 
2->8 
50.25-1 
50.5-> 16 
10.5 
0.5-4 
0.5-2 
0.5-> 128 
0.5-4 
1->8 
50.25 
10.5 
50.5 
0.5-16 
0.25-8 
1->128 
1-128 
8->8 
50.25-1 
50.5->16 
50.5-4 
0.5-64 
0.5-2 
1->128 
1-4 
1-64 
1->8 
10.25 
50.5 
10.5 
1-8 
1->128 
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O r w m  (4 Antimicrobial agent 50% 90% Range 
Mebsiella oryfocn (1 0) 
Klebsiella pneurnoniae (20) 
Morganella morgnnii (10) 
Proreus mirabilis (20) 
Proreus vulgaris (10) 
Providencia rettgeri (1 0) 
ApalcillidRo 48-1220 (2 pg/mL) 
Apalch/Ro 48-1220 (4 pg/mL) 
Apalcdhn 
Piperacillin/Tazobactam 
Ticarcillin/Clawlanate 
Amoxic&n/Clavulanate 
Imipenem 
Ceftavdime 
Cefepime 
Apalc&n/Ro 48-1220 (2 pg/mL) 
ApalcillidRo 48-1220 (4 pg/mL) 
Apalcan 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
AmoxiciUm/Clavulanate 
Imipenem 
Ceftazimme 
Cefepime 
ApalcillidRo 48-1220 (2 pg/mL) 
Apalc&n/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcilkn/Ro 48-1220 (2 pg/mL) 
ApalcillidRo 48-1220 (4 pg/mL) 
Apalcillin 
Piperac&n/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicdin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalc&n/Ro 48-1220 (2 pg/mL) 
Apalcfin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Cefiazidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
TicarcilWClavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Cefiazidime 
Cefepime 
1 
1 
16 
2 
8 
4 
50.25 
50.5 
50.5 
2 
4 
8 
4 
4 
2 
50.25 
50.5 
10.5 
0.5 
0.5 
2 
0.25 
1 
> 8  
1 
50.5 
50.5 
0.25 
0.25 
0.5 
0.25 
0.5 
1 
2 
50.5 
50.5 
0.5 
0.5 
32 
0.5 
0.5 
8 
0.5 
50.5 
50.5 
1 
0.5 
1 
0.25 
0.5 
> 8  
1 
50.5 
50.5 
128 
32 
r128  
32 
> 128 
> 8  
50.25 
10.5 
50.5 
4 
4 
16 
32 
8 
8 
10.25 
10.5 
10.5 
2 
2 
8 
1 
8 
> 8  
2 
50.5 
50.5 
0.5 
0.5 
2 
0.5 
0.5 
2 
4 
10.5 
50.5 
1 
1 
>128 
1 
1 
>8 
2 
1 
50.5 
4 
2 
> 128 
2 
64 
>8 
4 
1 
50.5 
1->128 
1-2128 
4->128 
1->128 
2-2 128 
2->8 
50.25 
10.5 
50.5 
2->128 
4->128 
1-64 
2-2128 
2-2 128 
2->8 
10.25 
50.5 
10.5 
0.5-4 
0.5-4 
1-128 
0.25-1 
0.5-16 
2 8  
0.5-2 
50.5-16 
50.5 
0.12-2 
0.12-2 
50.06->128 
0.12-0.5 
0.12-1 
0.5-8 
10.25-8 
50.5-2 
50.5-2 
0.25-1 
0.25-2 
1->128 
0.12-1 
0.5-2 
8->8 
10.25-2 
10.5 
10.5-4 
0.12-32 
0.12-32 
0.12->128 
0.12-128 
1->8 
10.25-4 
50.5-2 
0.12-4 
50.5 
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Table 1 continued 
MIC (pg/mL) 
Organism (n) Anhmicrobial agent 50% 90% Range 
Providencia stuartii (10) Apalcillin/Ro 48-1220 (2 pg/mL.) 
Apalcillin/Ro 48-1220 (4 pg/mL.) 
Apalcdhn 
Piperac&n/Tazobactam 
Ticarc&n/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Salmonella enterifidis (10) 
Serratia marcescens (20) 
Shigella species (10) 
Ersinia enrerocolitica (1 0)  
Haemophilus injuenzae 
8-lactamase-positive (20) 
B-lactamase-negative (20) 
0-lactamase-negative 
ampicillin-resistant (10) 
Apalcillin/Ro 48-1220 (2 pg/g/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalc&n/Ro 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL.) 
Apalcillin 
Piperacillin/Tazobaccam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
ApalcilldRo 48-1220 (2 pg/mL.) 
Apalcillin/Ro 48-1220 (4 pg/mL.) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 pg/mL.) 
ApalcilldRo 48-1220 (4 pg/mL.) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcdlin/Clavulanate 
AmoxicillidClavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Apalc&n/Ro 48-1220 (4 pg/mL) 
Apalcillin 
4 
4 
8 
2 
2 
>8 
1 
50.5 
50.5 
2 
2 
2 
2 
1 
0.5 
50.25 
10.5 
10.5 
2 
2 
4 
1 
4 
>8  
0.5 
50.5 
50.5 
1 
1 
>128 
2 
64 
8 .  
50.25 
10.5 
50.5 
0.5 
0.25 
4 
0.5 
2 
>8 
50.25 
50.5 
50.5 
0.06 
16 
0.06 
0.06 
0.5 
1 
32 
16 
64 
2 
16 
>8 
2 
8 
2 
2 
2 
64 
4 
64 
8 
50.25 
50.5 
50.5 
8 
8 
32 
8 
16 
>8  
4 
50.5 
50.5 
1 
1 
>128 
8 
>128 
>8 
10.25 
50.5 
10.5 
1 
0.5 
16 
4 
32 
>8 
50.25 
4 
10.5 
0.12 
16 
0.12 
0.12 
1 
1 
1-64 
1-64 
0.5->128 
1-16 
0.25-16 
> 8  
0.5->8 
50.5-216 
50.5-> 16 
1-2 
1-4 
1->128 
2-4 
1-64 
0.5->8 
50.25 
10.5 
50.5 
2-128 
2-64 
2-128 
0.5-64 
2-64 
8->8 
50.25-4 
10.5-1 
50.5-1 
0.5-2 
0.25-2 
64->128 
1-16 
8->8 
50.25 
50.5 
50.5 
0.12-64 
0.12-64 
4->128 
0.25->128 
1-32 
1->8 
50.25-8 
10.5->16 
50.5-16 
32->128 
0.03-0.12 
2->32 
0.03-0.25 
0.03-0.5 
0.06-1 
0.12-1 
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MIC (pg/mL) 
Organism (n) Antimicrobial agent 50% 90% Range 
Moraxella catanhalis 
BRO-I (10) 
BRO-I1 (10) 
8-lactamase-negative (10) 
Neissm’a gonowhoeae 
Penicillin-resistant (10) 
Penicfin-susceptible (20) 
Penicillinase-producing (19) 
Neisseria meningitidis (10) 
Neissm’a species (10) 
Acinetobacter species (20) 
Pseudomonas aemginosa (50) 
ApalcillidRo 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL.) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amaxicilltn/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 pg/mL) 
ApalcillidRo 48-1220 (4 pg/mL.) 
Apalcih 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
ApalcillidRo 48-1220 (4 pg/mL) 
Apalcillin 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Apalcih/Ro 48-1220 (4 pg/mL) 
Apalcdhn 
Apalcillin/Ro 48-1220 (4 &mL) 
Apalcillin 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
ApalcillinIRo 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
10.06 
10.06 
10.06 
10.06 
50.06 
10.25 
10.25 
50.5 
10.5 
50.06 
50.06 
10.06 
10.06 
50.06 
10.25 
10.25 
10.5 
50.5 
10.06 
10.06 
10.06 
10.06 
10.06 
10.25 
10.25 
10.5 
50.5 
0.06 
0.5 
50.008 
0.25 
10.008 
8 
10.008 
0.06 
1 
0.5 
0.25 
10.06 
2 
4 
8 
8 
10.25 
4 
4 
2 
2 
2 
4 
10.06 
10.06 
0.12 
10.06 
10.06 
50.25 
10.25 
10.5 
1 
50.06 
50.06 
0.12 
50.06 
50.06 
10.25 
10.25 
50.5 
50.5 
10.06 
10.06 
50.06 
10.06 
50.06 
10.25 
10.25 
1 
10.5 
1 
2 
0.25 
0.5 
10.008 
8 
10.008 
0.12 
8 
16 
2 
0.25 
16 
16 
8 
>8 
50.25 
4 
8 
8 
4 
16 
32 
10.06 
50.06 
50.06-0.25 
10.06 
10.06 
50.25 
10.25 
10.5 
50.5-2 
10.06-0.12 
10.06 
10.06-0.12 
50.06 
50.06 
10.25 
50.25 
10.5 
50.5 
10.06 
50.06 
50.06 
50.06 
10.25 
10.25 
50.5-1 
10.5 
10.06-0.12 
50.008-1 
0.25-2 
1 0.008-0.25 
0.03-8 
10.008-0.25 
1->32 
50.008-0.12 
0.03-0.25 
0.03-32 
0.12-32 
10.06-1 28 
10.06-128 
0.12->128 
0.25->128 
2->8 
10.25-0.5 
10.5-> 16 
50.52- 16 
10.06->128 
0.5-64 
0.5-32 
0.5-128 
2->128 
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MIC (pg/mL) 
Organism (n)  Antimicrobial agent 50% 90% Range 
Stenotrophomonaz maltophilia (20) 
Bacteroidesfragilis (3 1) 
Ticarcillin/Clavulanate 
Amoxicdlin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 p.g/mL) 
Apalcillin 
Piperacillin/Tazobactam 
TicarcilldClavulanate 
AmoxicdldClavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcdlin/Ro 48-1220 (4 pg/mL) 
ApalciUln 
32 
2 8  
1 
2 
2 
1 
1 
1 
4 
1 
>8 
2 8  
2 
8 
2 
32 
128 
>8 
1 
16 
8 
8 
2 
8 
16 
4 
>8 
>8 
16 
8 
8 
> 128 
8->128 
>8 
50.25-8 
50.5-> 16 
60.5-> 16 
0.25-128 
5 0.06-1 28 
0.12-128 
0.5-64 
0.25-128 
50.25->8 
0.25->8 
50.5->16 
50.5->16 
50.06-32 
8-> 128 
Table 2 In vim activity of antimicrobial drugs tested against 288 gram-positive bacteria 
MIC (pg/mL) 
Organism (n) Antimicrobial agent 50% 90% Range 
Staphylococcus aureus 
Oxacihn-susceptible (20) Apalcillin/Ro 48-1220 (2 p g / d )  
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcilhn 
Piperac&n/Tazobactam 
Ticarcllkn/Clavulanate 
Amoxicillin/Clavulanate 
lmipenem 
Ceftazidime 
Cefepime 
ApalcillidRo 48-1220 (2 pg/mL) 
ApalcillidRo 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Oxacllkn-resistant (10) 
Imipenem 
Ceftazibme 
Cefepime 
Staphylococcus epidermidis 
Oxacillin-susceptible (24) ApalcillidRo 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
PiperacillidTazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Staphylococcus haemolytim 
Oxacillin-susceptible (10) Apalcillin/Ro 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
0.5 
0.5 
2 
0.5 
1 
0.5 
50.25 
4 
2 
16' 
16 
32 
32 
32 
>8 
2 
> 16 
> 16 
0.12 
0.12 
1 
0.12 
0.25 
50.25 
50.25 
4 
50.5 
0.25 
0.25 
0.5 
0.5 
8 
0.5 
2 
1 
50.25 
8 
2 
16 
16 
64 
32 
64 
>8 
>8 
>16 
>16 
0.25 
0.5 
2 
0.5 
1 
0.5 
50.25 
4 
1 
0.5 
0.5 
0.25-0.5 
0.25-1 
0.25-8 
50.25-1 
0.5-2 
50.25-1 
50.25 
2-8 
1-2 
2-32 
4-32 
4-128 
16->128 
4->8 
50.25->8 
16->16 
4-64 
4->16 
50.06-0.5 
50.06-0.5 
0.12-8 
50.  06- 1 
0.12-4 
10.25-1 
50.25 
1-16 
50.5-4 
0.12-1 
10.06-0.5 
9 4  
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Organism (n) Antimicrobial agent 50% 90% Range 
Coagulase-negative staphylococcus 
Oxacillin-susceptible (20)’ 
Streptococcus pneumoniae (32) 
Viridans streptococcus (25) 
Streptococcus agakactiae (20) 
streptococcus pyogenes (22) 
Sfreptococcus groups C and G (11) 
Enterococcwfaecalis (22) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/ClavuIanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 &mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactarn 
Ticarcillin/Clavulanate 
AmoxicillidClavulante 
Apalcillin/Ro 48-1220 (2 pg/mL) 
ApalcillidRo 48-1220 (4 pg/mL) 
Apalcillin 
PipcracillidTazobactam 
Ticarcillin/Clavulanate 
Amoxicillin/Clavulanate 
Apalc&n/Ro 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
AmoxicillidClavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcillin/Ro 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
TicarcillinXlavulanate 
Amoxicillin/Clavulanate 
Apal~illinlR~ 48-1220 (2 &mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticanillin/Clavulanate 
Amoxicillin/Clavulanate 
Apalcillin/Ro 48-1220 (2 pg/mL) 
Apalc&n/Ro 48-1220 (4 p g / d )  
Apalcillin 
0.5 
0.25 
1 
10.25 
10.25 
8 
1 
0.25 
0.25 
1 
0.5 
0.5 
0.25 
10.25 
4 
0.5 
50.06 
10.06 
50.06 
10.06 
4 
10.25 
0.12 
0.25 
0.25 
0.12 
2 
50.25 
0.12 
0.12 
0.12 
0.12 
1 
50.25 
10.25 
10.5 
10.5 
10.06 
10.06 
10.06 
50.06 
0.25 
10.25 
10.06 
50.06 
10.06 
10.06 
0.25 
50.25 
2 
2 
2 
2 
0.5 
1 
0.5 
50.25 
8 
2 
0.5 
0.5 
2 
1 
1 
0.5 
10.25 
16 
2 
0.25 
0.25 
0.5 
1 
16 
10.25 
4 
4 
4 
8 
16 
4 
0.12 
0.12 
0.12 
0.25 
2 
10.25 
50.25 
50.5 
10.5 
10.06 
50.06 
50.06 
10.06 
0.5 
10.25 
0.12 
0.12 
0.12 
10.06 
1 
10.25 
4 
4 
4 
0.12-32 
10.06-0.5 
0.12-2 
10.25-0.5 
10.25 
2-16 
10.5-2 
0.12-0.5 
10.06-0.5 
0.12-8 
0.12-1 
0.12-2 
0.25-0.5 
50.25 
2-16 
0.5-2 
50.06-1 
10.06-2 
10.06-2 
10.06-4 
0.12-64 
10.25-0.5 
10.06-8 
10.06-8 
10.06-16 
10.25-8 
10.06-0.25 
10.06-0.12 
10.06-0.12 
50.06-0.25 
0.5-2 
10.25 
10.25 
50.5 
50.5 
10.06-0.12 
10.06-0.12 
10.06-0.12 
10.06 
0.25-1 
10.25 
10.06-0.12 
10.06-0.12 
50.06 
50.25 
1->128 
1->128 
10.06-8 
1->128 
10.06-0.25 
0.25-2 
1->128 
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MIC olg/mL) 
Organism (n) Antimicrobial agent 50% 90% Range 
PiperacillidTazobactam 2 4 1->128 
Ticarcillin/Clavulanate 64 64 16->128 
Amoxicillin/Clavulanate 0.5 0.5 10.25->8 
Imipenem 0.5 1 0.5->8 
Cefepime >16 > 16 8->16 
Ceftazidime >16 > 16 16->16 
Enterococcusfaecium (1 0) 
Enterococcus species 
Bacillus cereus (7) 
Corynebacerium jeikeium (1 1) 
ApalcillinIRo 48-1220 (2 pg/mL) 
Apalc&n/Ro 48-1220 (4 pg/mL) 
A p a l c h  
Piperacillin/Tazobactam 
Ticarcillin/Clavulanate 
AmoxicilldClavulanate 
Imipenem 
Ceftazidime 
Cefepime 
Apalcilltn/Ro 48-1220 (2 pg/mL) 
Apalcillin/Ro 48-1220 (4 pg/mL) 
Apalcillin 
Piperacillin/Tazobactam 
Ticarcillin/Clavdanate 
AmoxicdlidClavulanate 
Imipenem 
Ceftazidime 
Cefepime 
32 
32 
32 
32 
2128 
2 
> 8  
> 16 
>16 
4 
4 
2 
4 
32 
S0.25 
0.5 
>16 
> 16 
128 
128 
128 
>128 
,128 
>8 
>8  
>16 
>16 
64 
64 
64 
64 
> 128 
8 
4 
>16 
>16 
8->128 
4->128 
8->128 
16->128 
64->128 
0.5-28 
2->8 
716  
> 16 
1-128 
1-64 
1-128 
4->128 
50.25->8 
10.25->8 
> 16 
2-128 
> 16 
Apalcillin/Ro 48-1220 (2 pg/mL) 0.5 - 0.25-0.5 
Apalcillin/Ro 48-1220 (4 pg/mL) 0.25 - 0.12 -0.5 
Apalcillin 1 - 0.5-1 
Piperacillin/Tazobactam 0.5 - 0.25-1 
TicarciILidClavulanate 64 - 16-128 
Amoxicillin/Clavulanate 4 2-8 - 
Apalcillin/Ro 48-1220 (2 pg/mL) r128  > 128 > 128 
Apalcillin/Ro 48-1220 (4 pg/mL) > 128 > 128 32-> 128 
Apdcilhn >128 > 128 128->128 
Piperacillin/Tazobactam r128  r128 16->128 
TicarciUin/Clavulanate > 128 > 128 > 128 
Amoxlcilhn/Clavulanate > 8  >8 >8  
10.06-16 
Apalcillin 0.25 1 1 0.06-1 6 
Closhidiurn species (13) Apalcillin/Ro 48-1220 (4 pg/mL) 0.12 0.25 50.06-2 
Peptostreptococcus species (21) Apalcillin/Ro 48-1220 (4 pg/mL) 0.12 0.5 
50.06-1 Apalcillin 0.12 0.5 
a = includes S. auricularis (1). S. capitis (l), S. cohnii (l), S. hominis (5), S. saprophyticus (5), S. scurii (l), S. simulans (4) and S. warneni (2). 
b = includes E. avium (l), E.  cussel@avus (l), E.  durans (2), E. gallinanrm (2), E. hirae (1). E. mundtii (1) and E. rajinosus (2). 
AU of the drugs tested were highly active against 
Streptococcus species except for the viridans group and 
pneumococci, where some of the strains were resistant 
to ticarcillin/clavulanate. Addition of the inhibitor (Ro 
48-1220) did not enhance the activity of apalcillin 
against S. pneumoniae or other streptococci. However, 
MICs for the penicilhn-resistant strains were two- to 
eightfold higher than the penicillin-susceptible isolates 
(data not shown) because of the potentially altered 
penicillin-binding proteins (PBPs). Ceftazidime and 
cefepime were both inactive when tested against 
enterococci (MICgo >16 pg/mL). Among the other 
drugs tested, ticarcillin/clavulanic acid was least active 
against all enterococci (MIC90 64 to >128 p g / d ) .  Of 
the other enterococci examined, E.  faeciurn was most 
resistant to all of the drugs whereas imipenem and 
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amoxicillin/clavulanic acid demonstrated the best 
activity against the remaining strains. Corynebacterium 
jeikeium was highly resistant to the drugs used in this 
study. Bacillus cereus strains were resistant to ticarcillin/ 
clavulanate (MI& 64 pg/mL), but susceptible to 
apalcihn, piperacdin/tazobactam and the apalcillid 
R o  48-1220 combinations. The gram-positive anae- 
robes were susceptible to both apalcillin alone and 
combined with R o  48-1220, although synergy was 
unusual. 
The results of apalcillin with and without its 
inhibitor (Ro 48-1220) in tests against bacterial species 
rarely isolated in the clinical setting (Table 3) indicate 
that the highest MIC values occurred among Serrutia 
liquefaciens, Flavobacterium species and Burkkolderia 
Table 3 Minimum inhibitory concentrations (MICs) of 20 
infi-equently isolated bacterial species 
MICs (ue/mL) 
Apalcilhn Apalcillin/Ro 48- 
Organism (n) (4 pg/mL)’ 1220 (4 pg/mL)’ 
Enrerobacter saknzakii (2) 
Enterobacfer taylorue (2) 
Ha&ia alm’ (2) 
Klebsiella ozaenae (1) 
Salmonella typhi (2) 
Sendtia liqu&iens (1) 
Aeromonas hydrophila (2) 
Achmmobacter xylosoxidans (2) 
Fluvobacterium species (1) 16 
Burkholderia cepacia (2) 4, 64 
Listeria monocytogenes (2) 1, 1 
Pseudomo~sjuomcens (1) 4 
1, 1 
2, 2 
0.5, 2 
0.12 
1, 1 
8 
0.25, 1 
0.12, 0.25 
16 
1, 1 
4, 32 
4 
a = fxed concentration 
Table 4 Apalcillin and apalcillin/Ro 48-1220 (4 pg/mL fixed 
broad-spectrum drugs 
(Pseudomonas) cepacia isolates. However, all of these 
organisms were considered susceptible. In addition, 
there were a few examples of R o  48-1220 synergy 
(Klebsiella ozaenae, Aeromonas hydrophila) when testing 
apalcillin against these species. 
Included in the study organism population were 
204 strains identified as either fluoroquinolone-, 
ceftazidime- or gentamicin-resistant. The MICs for 
’apalcillin and apalclllin/Ro 48-1220 (Table 4) reveal 
that the fluoroquinolone-resistant organisms were the 
least susceptible group, with only 39% and 66% of 
strains being susceptible to apalcdhn or apalcillin/Ro 
48-1220 (MICs 5 16 pg/mL), respectively. The greatest 
activity was seen with apalcillin/Ro 48-1220 tested 
against the gentamicin-resistant organisms (91% suscep- 
tible). ApalcillidRo 48-1220 was also active against 
78% of ceftazidime-resistant (MICs >16 g/mL) isolates 
and an addtional 12% of strains had intermediate (32 
or 64 pg/mL) MICs. Overall, the addition of R o  48- 
1220 to apalcillin increased the number of susceptible 
organisms by an average of 27% compared with the 
apalcfin-susceptible rate. 
The MICs for 12 E. coli strains and 23 Klebsiella 
species isolates that produce extended-spectrum B- 
lactamases (ESBL) are shown in Table 5. Imipenem was 
the most potent drug tested, with MICs 10.25 pg/mL 
against E. coli, and imipenem was the only drug that 
was active against Klebsiella species of the ESBL 
phenotype (MIC50 50.25 pg/mL). For the E.  coli 
producing TEM-derived enzymes, there was a marked 
decrease in MICs (>128 pg/mL to 1 or 4 pg/mL) when 
the B-lactamase inhibitor (4 pg/mL) was combined 
with apalcillin. Thus, the addtion of R o  48-1220 
produced a significant (>four-fold) decrease of the 
concentration) activity against 204 organisms resistant to other 
Cumulative % inhibited at MIC (pg/mL) 
Resistant 
organisms (n) Antimicrobial agent 0.12 0.25 0.5 1 2 4 8 16 32 64 128 
Fluomquinolone- Apalcillin 0 0 2 10 20 28 31 39 49 57 69 
resistant (61)’ Apalcillin/Ro 48-1220 0 0 10 20 28 40 43 66 74 84 92 
Ceftazidime- Apalcillin 0 0 3 15 36 42 46 49 58 67 85 
resistant (90)b ApalcilhdRo 48-1220 1 7 9 22 43 61 68 78 82 90 96 
Gentamicin- Apalcillin 2 9 13 28 41 54 62 66 66 73 79 
resistant (53)F Apalcillin/Ro48-1220 4 15 28 56 77 81 87 91 95 97 100 
a = Enterobacteriaceae (9 species, 30 strains), enterococci (2 species, 20 strains), Staphylocom a u m  (8 strains), coagulase-negative 
staphylococci (3 species, 3 strains). 
b = enterococci (9 species, 45 strains), Enterobacteriaceae (5 species, 19 strains), S. aureus (10 strains), Bacillus cereus (7 strains), 
Listeria monocytogenes (2 strains), non-enteric gram-negative bacilli (8 strains). 
c = Enterobacteriaceae (10 species, 27 strains), Pseudomom amginosa (5 strains), Stenomphomonar maltophilia (16 strains), gram-negative non- 
enteric bacilli (3 species, 5 strains). 
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penicillin MIC, and resulted in these strains becoming 
susceptible in terms of the hypothesized breakpoint 
MICs. In comparison, in strains with the SHV-derived 
ESBLs, only SHV-3 and -4 were affected by the 
addition of Ro 48-1220 to apalcillin. Piperacillin/ 
tazobactam was generally similar to apalcillin/Ro 48- 
1220 in its activity against the E. coli strains producing 
an ESBL, but was more potent against SHV enzyme- 
containing strains. All of the ESBL-producing enteric 
bacilli were resistant to ceftazidime and ticarcilhd 
clavulanate. 
Regarding the effects of altering the in vitro test 
parameters on the activity of apalcillin/Ro 48-1220 
(Table 6), four ofthe strains became potentially resistant 
(MICs >16 pg/mL) when the inoculum concentration 
was increased from lo5 to lo6 cfidspot. An increase in 
magnesium cation levels, addition of 5% sheep blood 
cells, alterations in incubation conditions or changes in 
medium pH levels did not significantly affect the 
activity of apalcillin/Ro 48-1220. 
Intermethod comparison of agar dilution and 
broth microdilution results for apalcillin and apalcillid 
R o  48-1220 against 25 selected strains (Table 7) showed 
closest agreement with apalcillin/Ro 48-1220 (fixed 4 
p g / d  concentration) with a 60 % absolute agreement 
between the results of both methods. A majority of 
the apalcilhn broth MICs (52%) were one or two logz 
dilution steps higher than agar MICs, whereas 
Table 5 Activity of selected antimicrobial agents against 35 bacterial strains producing extended-spectrum (B-lactamases 
Organism (n) I3-lactamase Apalcillin Apal/Ro 48-1220 Pip/Taz imipenem Ceftazirllme 
Escherichia coli (12)' TEM-3 > 128 1 2 50.25 >16 
TEM-4 >128 1 2 10.25 >16 
TEM-5 64 1 2 10.25 1 1 6  
TEM-6 >128 4 32 50.25 >16 
TEM-7 > 128 2 2 10.25 >16 
TEM-8 >128 1 2 50.25 >16 
TEM-9 > 128 1 2 50.25 >16 
SHV-2 > 128 > 128 4 50.25 16 
SHV-3 > 128 64 8 50.25 16 
SHV-4 >128 16 2 50.25 >16 
SHV-5 >128 > 128 >128 50.25 >16 
Unknownb > 128 2 4 10.25 >16 
Klebsiella species (23) Unknownb > 128' 128' 128' 50.25' > 16' 
Apal = apalcillin; Pip/Taz = piperacillin/tazobactam. 
a = TEM-3 to -9 and SHV-2 to -5 were transconjugates of C-600 [6]. 
b = Chical strains showing plasmid-mediated extended-spectrum R-lacramase activity. 
c = MIC5o (pg/nL) for all 23 strains tested. 
Table 6 Effects of inoculum concentration, pH, supplements, divalent cation levels and type of incubation on apalcillin/Ro 
48-1220 (4 pg/mL. fuced concentration) activity for 10 selected bacterial strains 
MIC (&mL) 
Organism 
~~ ~ ~~~ 
Mg++ 
inoculum concentration (cfidspot) PH' (mg/ml) incubation 
103 104 105 106 5% SBC 6.0 8.0 x 10 5% coz ANA 
Citrobacterfreundii 1 1 2 8 1 2 1 1 1 0.5 
Enterobacter cloacae 2 2 4 >16 1 2 1 2 2 1 
Escherithia coli 1 1 1 2 1 2 0.5 1 1 0.5 
Klebsiella pneumonia 1 2 2 > 16 1 4 1 1 2 0.5 
Serratia marcescens 4 4 8 > 16 4 8 2 4 4 2 
Pseudomonos aeruginosa 1 2 2 4 1 2 1 2 2 
Pseudomonos aeruginosa 2 2 2 > 16 1 2 1 2 2 
Staphylococcus aureus 1 1 1 2 1 0.5 1 1 
Stuphylococrus epidermidis 0.5 0.5 1 2 1 0.5 50.12 0.5 0.5 1 
Enterococcus faecalis 4 2 4 4 2 1 8 2 1 1 
0.5 0.5 
SBC = sheep blood cells; x 10 = magnesium at 100 p g / d  or 10 ames the usual urine level; ANA = anaerobic incubation. 
a = compare with lo4 cfulspot for pH 7.2. 
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Table 7 Comparison of the apalcillin/Ko 48-1220 MICs tested by reference agar dilution and broth microdilution methods 
(25 selected strains) 
~~ 
Agar M1C:Broth MIC ratio (%) 
Antimicrobial agent 50.25 0.5 1 2 2 4  
~~ ~~ 
Apalcillin 12 40 36 12 0 
ApalcillidRo 48-1220 (2 pg/niL.) 0 16 44 40 0 
Apalc&/Ro 48-1220 (4 pg/mL.) 0 8 60 28 4 
apalcillin/Ro 48-1220 results had a 96 to 100% inter- 
method endpoint agreement * one log2 dilution step. 
Ten bacterial strains were examined for hfferences 
in MIC and MBC levels of apalcdlin/Ro 48-1220 
(Table 8). An average of one log2 dilution increase in 
the drug MIC was necessary to achieve killing. The 
apalcikn/Ro 48-1220 MBCs (0.25 to 4 pg/mL) were 
well within the susceptible MIC range (116 pg/mL) 
used for similar inhibitor combinations such as 
ticarcillin/clavulanic acid. 
DISCUSSION 
This results of this study confirm previous published 
reports in which apalcillin demonstrated activity 
comparable to piperacillin against most Enterobacter- 
iaceae, Pseudomonas species, B-lactamase-producing 
fastidious gram-negative bacilli (H. injuenzae, M .  
catawhalis, N. gonorrhoeae), Streptococcus species, oxacillin- 
susceptible Staphylocoms species and anaerobic organ- 
isms [21-241. Pharmacokinetic studies indicate that 
apalcillin possesses a longer serum elimination half-life 
than piperacillin and a higher degree of protein binding 
which was reversible [23,24,28]. When combined with 
the described 0-lactaqase-inhibitor R o  48-1220 (at a 
Table 8 Minimum inhibitory concentration (MIC) and 
minimum bactericidal concentration (MBC) results for 
apalcillin/Ro 48-1220 (4 p g / d  fixed concentration) for 
10 typical bacterial isolates 
Concentration (pg/mL) 
Organism MIC MBC 
Citrobacter jeundii  
Enterobacter cloacae 
Escherichia colt* 
Klebsiella pneumoniae 
Morganella morganii 
Sewatia marcescens 
Staphylococrus aureuZ 
Staphylococcus epidermidis 
Enterococcus faecaliZ 
Pseudomonas aarginosC 
1 
1 
1 
1 
1 
2 
0.25 
0.5 
2 
1 
1 
2 
2 
1 
1 
2 
0.25 
1 
2 
4 
~~ 
a = National Committee for Clinical Laboratory Standards quality- 
control strains [18]. 
fixed 4 pg/mL concentration) or tazobactam [14], 
apalcillin activity was significantly enhanced. In fact, 
among all the gram-negative aerobic and anaerobic 
isolates tested, only K. oxytocu (MICw 32 pg/rnL.) was 
marginally inhibited by apalcillin/Ro 48-1220. These 
strains produce, via chromosomally mediated genetics, 
a Bush group 2b’ R-lactamase [2]. The activity of 
apalcillin/Ro 48-1220 was potent against aerobic 
gram-positive organisms (MI& 10.06 to 4 pg/mL) 
with the exceptions of C. jeikeium (MIC90 > 128 
pg/mL), oxacillin-resistant staphylococci (MICw 16 
p g l d ) ,  and Enterococcus species other than E. faecalis 
64 to 128 pg/mL). However, these cited 
species were also more resistant to the other drugs 
tested. 
During the past decade, the increase in the 
isolation of organisms with extended-spectrum B- 
lactamases (ESBL), which confer resistance to third- 
generation cephalosporins and monobactams, has 
caused great concern among researchers and clinicians 
[4-81. Due to the many differences in the enzyme 
substrate affinities, rates of hydrolysis, and resistance or 
susceptibility to inhibitors, these enzymes have been 
extensively analyzed and characterized [ 1-8,201. Some 
studies have demonstrated that the plasmids that 
determine the ESBLs are easily transferable whereas 
other investigators suggest that we may be wimessing 
the spontaneous emergence of different types of R- 
lactamases [8]. Although some B-lactam/R-lactamase- 
inhibitor combinations remain active in vitro against 
strains harboring an ESBL, these organisms can be 
refractory in vivo to enzyme inhibition and, ulti- 
mately, to the therapy of some infections [4-71. In 
general, previous investigations have concluded that 
piperacillin/tazobactam is the most active R-lactam/ 
B-lactamase inhibitor combination when tested against 
ESBL organisms and, also, that it has the widest clinical 
spectrum [4,5,11,12,14,18]. Although tazobactam 
alone has limited antibacterial activity, it is a potent 
inhibitor of many types of 0-lactamase [12,15]. In this 
report, apalcillin/Ro 48-1220 demonstrated activity 
comparable to that of piperacillin/tazobactam against 
E .  coli containing TEM-derived enzymes, but was less 
successful against the mutant-SHV B-lactamases. Some 
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synergy with Ro 48-1220 [25] was also observed 
against Bush group 1 D-lactamases (Ambler class C) 
found among C.freundii and Enterobacter species isolates. 
This R o  48-1220 effect appears to be wider than that 
reported for other inhbitors. The overall spectrum for 
the combination ofapalcillin with R o  48-1220 appears 
to at least equal that of piperacillin/tazobactam. 
In conclusion, the most potent apalcillin/Ro 
48-1220 combination used Ro  48-1220 [25] at  a 
fixed concentration of 4 p g / d ,  the same amount of 
inhibitor as in susceptibility tests in vitro of piperacillid 
tazobactam [19,26,27]. Given the favorable pharmaco- 
kinetics of apalcillin compared with peer drugs and the 
greater activity of apalcillin/Ro 48-1220 compared 
with piperacillidtazobactam against many species, the 
former represents a potential therapeutic alternative. In 
addition, ceftazidime-, gentamicin- or ciprotloxacin- 
resistant organisms may be successfully inhibited by 
apalcillin/Ro 48-1220. Therefore, further analyses 
of apalcillin/Ro 48-1220 appear to be warranted, 
including human toxicology, pharmacokinetics and in 
vivo trials. 
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